| Japanese |
|---|
| Title | 補助人工心臓施行時における凝血学的パラメータの評価 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 田中國義*, 佐藤友昭*, 矢田公*, 湯淺浩*, 草川實*, 那須通寛**, 岡田行功**, 庄村東洋** |
|---|
| Authors(kana) | |
|---|
| Organization | *三重大学医学部胸部外科学教室, **神戸中央市民病院胸部外科 |
|---|
| Journal | 循環制御 |
|---|
| Volume | 11 |
|---|
| Number | 4 |
|---|
| Page | 517-521 |
|---|
| Year/Month | 1990/ |
|---|
| Article | 原著 |
|---|
| Publisher | 日本循環制御医学会 |
|---|
| Abstract | 「要旨」開心術後, 人工心肺から離脱不能に陥った2症例に対し, 左心補助心臓(Left Ventricular Assist Device, LVAD)を使用し, その凝血学的パラメータの推移を検討した. いずれの症例も, activated coagulation time(ACT), prothrombin time(PT), activated partial thromboplastin time(APTT)は正常ないし軽度延長を示すに留まったが, Fibrinopeptide A(FPA)およびThrombin/antithrombin III complex(TAT)は, 装着後数日間のうちに著明に上昇し, その後低下傾向を示すものの終了時まで異常高値が持続した. さらにfibrinopeptide Bβ15-42(FPBβ15-42)およびα2 plasmin inhibitor/Plasmin complex(PIC)も同様にLVAD装着中は異常高値が持続した. 以上より, LVAD中は, 明らかな臨床所見は認めなくとも, 凝固系, 線溶系ともに強い活性化が起こっている事は明らかで, 予防的抗凝固療法の必要性が示唆された. |
|---|
| Practice | 基礎医学・関連科学 |
|---|
| Keywords | Left ventricular assist device, Coagulofibrinolysis, Anticoagulant, Thrombin-antithrombin III complex, α2 Plasmin inhibitor-plasmin complex |
|---|
| English |
|---|
| Title | Analysis of Hemostatic Parameters during Left Ventricular Assist Devices |
|---|
| Subtitle | |
|---|
| Authors | Kuniyoshi Tanaka*, Tomoaki Sato*, Isao Yada*, Hiroshi Yuasa*, Minoru Kusagawa*, Michihiro Nasu**, Yukikatsu Okada**, Toyo Shomura** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Thoracic Surgery Mie University School of Medicine, **Department of Thoracic Surgery Kobe General Hospital |
|---|
| Journal | Circulation Control |
|---|
| Volume | 11 |
|---|
| Number | 4 |
|---|
| Page | 517-521 |
|---|
| Year/Month | 1990/ |
|---|
| Article | Original article |
|---|
| Publisher | Japan Society of Circulation Control |
|---|
| Abstract | We evaluated the hemostatic alterations in two adult patients who were supported by left ventricular assist devices (LVADs) because of postcardiotomy heart failure. In both cases, instead of the normal or prolonged values of prothrombin time and activated partial thromboplastin time, fibrinopeptide A and thrombin-antithrombin III complex increased markedly during the first several days, and remained above normal over the entire procedure. Furthermore, fibrinopeptide Bβ15-42 and α2 Plasmin inhibitor-plasmin complex were also markedly increased over the entire course of LVAD treatment. These data show that the LVAD system strongly activates both the coagulation and the fibrinolytic system, even when thromboembolic or bleeding complications are not clinically evident. Anticoagulant therapy is mandatory for the safe management of LVAD treatment. |
|---|
| Practice | Basic medicine |
|---|
| Keywords | Left ventricular assist device, Coagulofibrinolysis, Anticoagulant, Thrombin-antithrombin III complex, α2 Plasmin inhibitor-plasmin complex |
|---|